Mipomersen is a Promising Therapy in the Management of Hypercholesterolemia: A Meta-Analysis of Randomized Controlled Trials
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Introduction By inhibiting apolipoprotein B (ApoB) synthesis, mipomersen can significantly reduce ApoB-containing lipoproteins in hypercholesterolemic patients.Objective This study sought to ascertain both the extent to which mipomersen can decrease ApoB-containing lipoproteins and the safety of mipomersen therapy.Methods Studies were identified through PubMed, CENTRAL, Embase, Clinical Trials, reviews, and reference lists of relevant papers. The efficacy endpoints were the changes in low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), ApoB, and lipoprotein (a) [Lp(a)]. The safety endpoints were the incidence of injection-site reactions, flu-like symptoms, and elevated transaminases.Results Six randomized controlled trials with 444 patients were included in the analysis. Compared with the placebo group, patients who received mipomersen therapy had a significant reduction in LDL-C (33.13%), as well as a reduction in non-HDL-C (31.70%), ApoB (33.27%), and LP(a) (26.34%). Mipomersen therapy was also associated with an obvious increase in injection-site reactions with an odds ratio (OR) of 14.15, flu-like symptoms with an OR of 2.07, and alanine aminotransferase levels ≥ 3 × the upper limit of normal with an OR of 11.21.Conclusions Mipomersen therapy is effective for lowering ApoB-containing lipoproteins in patients with severe hypercholesterolemia. Future studies exploring how to minimize side effects of mipomersen therapy are needed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While recent investigations have attempted to unravel the mechanism, it remains unclear. However, it appears to be distinct from that of statins, which also enhance LDLR function but do not lower circulating Lp(a) levels in humans.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [288]
In the citing paper
“In contrast to statins, inhibiting PCSK9 with mAbs also reduces Lp(a) plasma levels. Pooled results of phase II trials have shown that treatment leads to an Lp(a) reduction of about 30-40% [288,289].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [288]
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · cited 1×
“Heterogeneity of effects was assessed with Chi-squared tests and I(2); an I(2)[50 % was considered to indicate significant heterogeneity between the trials [17].”
MethodGrundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.002 · Cited by 3,845
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Lipoprotein(a) as a cardiovascular risk factor: current status
Nordestgaard, B. G., Chapman, M. J., Ray, K., Borén, J., Andreotti, F., Watts, G. F., Ginsberg, H., Amarenco, P., Catapano, A., Descamps, O. S., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq386 · Cited by 1,807 · cited 1×
“disease [35–39] and are also the targets of lipid-lowering therapy [24].”
Background
Research works printed but not linked: 1
- Genzyme and Isis provide update on CHMP opinion on KYNAMRO™ (mipomersen). Press release, Genyzme and Isis Pharmaceuticals. http://en.sanofi.com/Images/31557_20121214_KYNAMRO_en.pdf . Accessed 15 Nov 2013.
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
“Reactions at the injection site are the most common adverse effects observed in patients treated with mipomersen.(304) However, the main concerns regarding mipomersen’s safety are related to liver toxicity.”
Jacobson, T. A., Ito, M. K., Maki, K. C., Orringer, C. E., Bays, H. E., Jones, P. H., McKenney, J. M., Grundy, S. M., Gill, E. A., Wild, R. A., et al. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.02.003 · Cited by 773
Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target
Behbodikhah, J., Ahmed, S., Elyasi, A., Kasselman, L. J., De Leon, J., Glass, A. D., & Reiss, A. B. (2021) · Metabolites · doi:10.3390/metabo11100690 · Cited by 270
“The Friedewald equation, which is subject to inaccuracy in the presence of high triglycerides and other conditions like diabetes, estimates LDL-C as total cholesterol minus HDL-C and very-low-density cholesterol (VLDL-C), with VLDL-C estimated as triglycerides divided by a fixed factor of Metabolites 2021, 11, 690 6 o…”
BackgroundInfluentialFamilial hypercholesterolemia treatments: Guidelines and new therapies
Raal, F. J., Hovingh, G. K., & Catapano, A. L. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.06.859 · Cited by 194
Image-based detection and targeting of therapy resistance in pancreatic adenocarcinoma
Fox, R. G., Lytle, N. K., Jaquish, D. V., Park, F. D., Ito, T., Bajaj, J., Koechlein, C. S., Zimdahl, B., Yano, M., Kopp, J. L., et al. (2016) · Nature · doi:10.1038/nature17988 · Cited by 142
Mipomersen and its use in familial hypercholesterolemia
Parham, J. S., & Goldberg, A. C. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1550071 · Cited by 94
LP(a): Structure, Genetics, Associated Cardiovascular Risk, and Emerging Therapeutics
Tasdighi, E., Adhikari, R., Almaadawy, O., Leucker, T. M., & Blaha, M. J. (2023) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-031023-100609 · Cited by 72
RNA Therapeutics in Oncology: Advances, Challenges, and Future Directions
MacLeod, A. R., & Crooke, S. T. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.957 · Cited by 64
Pavía-López, A. A., Alcocer-Gamba, M. A., Ruiz-Gastélum, E. D., Mayorga-Butrón, J. L., Mehta, R., Díaz-Aragón, F. A., Aldrete-Velasco, J. A., López-Juárez, N., Cruz-Bautista, I., Chávez-Mendoza, A., et al. (2022) · Archivos de cardiología de México · doi:10.24875/acm.m22000081 · Cited by 58
The Biomarker and Therapeutic Potential of Mirna in Alzheimer’s Disease
Bekris, L. M., & Leverenz, J. B. (2015) · Neurodegenerative Disease Management · doi:10.2217/nmt.14.52 · Cited by 57
Bruikman, C. S., Stoekenbroek, R. M., Hovingh, G. K., & Kastelein, J. J. P. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.09.010 · Cited by 45
Grossman, T. R., Hettrick, L. A., Johnson, R. B., Hung, G., Peralta, R. Q., Watt, A. T., Henry, S. P., Adamson, P., Monia, B. P., & McCaleb, M. L. (2015) · Immunobiology · doi:10.1016/j.imbio.2015.08.001 · Cited by 39
Lipoprotein(a) in postmenopausal women: assessment of cardiovascular risk and therapeutic options
Anagnostis, P. G., Karras, S. Ν., Lambrinoudaki, I. V., Stevenson, J. C., & Goulis, D. G. (2016) · International Journal of Clinical Practice · doi:10.1111/ijcp.12903 · Cited by 36
The promising novel therapies for familial hypercholesterolemia
Chen, R., Lin, S., & Chen, X. (2022) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24552 · Cited by 32
Khoury, É., Brisson, D., Roy, N., Tremblay, G., & Gaudet, D. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1602606 · Cited by 31
Dyslipidemia: A Narrative Review on Pharmacotherapy
de Oliveira, L. D., de Assis, A. C. R., Giraldez, V. Z. R., Scudeler, T. L., & Soares, P. R. (2024) · Pharmaceuticals · doi:10.3390/ph17030289 · Cited by 30
“A meta-analysis observed an average reduction of 33% in apoB with the use of mipom-ersen, associated with reductions in LDL-C, non-HDL-C, TGs, and Lp(a) [163].”
MethodTreatment of Hypertriglyceridemia: a Review of Current Options
Vrablík, M., & Češka, R. (2015) · Physiological Research · doi:10.33549/physiolres.933199 · Cited by 28
Emerging Pharmacotherapy to Reduce Elevated Lipoprotein(a) Plasma Levels
Eraikhuemen, N., Lazaridis, D., & Dutton, M. T. (2020) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-020-00437-7 · Cited by 21
Gene-based therapies in lipidology: current status and future challenges
Gaudet, D., & Brisson, D. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000240 · Cited by 20
Staroseletz, Y., Miroshnichenko, S. K., Patutina, O., Bichenkova, E. V., Amirloo, B., Heyman, T., Chiglintseva, D., & Аркадьевна, З. М. (2021) · Molecules · doi:10.3390/molecules26061732 · Cited by 16
Novel therapeutic targets and agents for pediatric dyslipidemia
Sunil, B., Foster, C., Wilson, D. P., & Ashraf, A. P. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188211058323 · Cited by 15
Li, Z.-F., & Wu, N. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.911429 · Cited by 11
“…(Raal et al., 2010) and Lomitapide (MTP inhibitors) (D’Erasmo et al., 2017), both of which can promote liver triglycerides accumulation and increase transaminase, causing nonalcoholic fatty liver disease, have limited clinical application due to side effects (Li et al., 2014; Blom et al., 2016).”
BackgroundHeestermans, M., & van Vlijmen, B. J. M. (2017) · Thrombosis Journal · doi:10.1186/s12959-017-0130-8 · Cited by 10
“This specific downregulation allows more release of very low density lipoprotein (VLDL) from the liver to the bloodstream, which will cause a drop of LDL-cholestorol levels in plasma [69, 70].”
BackgroundTargeting Lipoprotein (a): an Evolving Therapeutic Landscape
Man, L. C., Kelly, E. M., & Duffy, D. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-015-0502-0 · Cited by 10
Amirloo, B., Staroseletz, Y., Yousaf, S., Clarke, D. J., Brown, T., Aojula, H. S., Аркадьевна, З. М., & Bichenkova, E. V. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab1273 · Cited by 9
Recent explanatory trials of the mode of action of drug therapies on lipoprotein metabolism
Chan, D. C., Barrett, P. H. R., & Watts, G. F. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000348 · Cited by 6
“Clinical studies in hypercholesterolaemic subjects, including familial hypercholesterolaemia, have shown that mipomersen, an antisense oligonucleotide (ASO) inhibitor of apoB synthesis, significantly lowers plasma LDL-cholesterol and apoB by up to 50% [29].”
BackgroundPirillo, A., & Catapano, A. L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809657-4.99567-x · Cited by 6
Lian, P., Zhu, W.-Q., Zhao, W.-X., Huang, P., Ran, J., Tang, Y., Huang, X., & Li, R. (2024) · Clinica Chimica Acta · doi:10.1016/j.cca.2024.119982 · Cited by 5
Updates on Non-Statin LDL-Lowering Therapy
Abdulla, A., Shalaby, M., Kumfa, P. N., Raja, M. W., Allencherril, J., & Sharifeh, T. A. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02028-3 · Cited by 5
Nuevos tratamientos para la hipercolesterolemia
Pintó, X., & Gómez, M. C. G. (2015) · Medicina Clínica · doi:10.1016/j.medcli.2015.01.016 · Cited by 5
Kegiatan Pemeriksaan Kadar Kolesterol pada Petugas dan Karyawan SMA Santo Yoseph, Cakung
Kosasih, R., Santoso, A. H., Jap, A. N., Destra, E., & Gunaidi, F. C. (2024) · Karunia Jurnal Hasil Pengabdian Masyarakat Indonesia · doi:10.58192/karunia.v3i4.2660 · Cited by 4
“( Emelyanchik et al., 2023; Girardi & Couto, 2023; N. Li et al., 2014) Perilaku hidup sehat dapat dilakukan dengan menghindari konsumsi alkohol berlebihan dan berhenti merokok.”
Advances in Hypercholesterolemia
Pirillo, A., Norata, G. D., & Catapano, A. L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12435-7 · Cited by 3
Pirillo, A., Casula, M., Baragetti, A., & Catapano, A. L. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15734-9.00001-7 · Cited by 3
Masana, L., & Ibarretxe, D. (2024) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2024.07.004 · Cited by 2
The emergence of gene therapy for rare diseases
Phillips, M. I., & Burns, A. B. (2014) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2014.978284 · Cited by 2
Antisense: Progress Towards Gene-Directed Cancer Therapy☆
Crooke, S. T., & MacLeod, A. R. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.98738-5 · Cited by 3
New agents for hypercholesterolemia
Pintó, X., & Gómez, M. C. G. (2016) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2016.04.058 · Cited by 2
Drug-Induced Fatty Liver Disease
Samala, N. R., & Chalasani, N. (2018) · Current Hepatology Reports · doi:10.1007/s11901-018-0418-6 · Cited by 2
Familial Hypercholesterolaemia: An Updated Overall Management
Kasim, N. A. M., Chua, Y. A., & Nawawi, H. M. (2020) · Journal of Clinical and Health Sciences · doi:10.24191/jchs.v5i2.11121 · Cited by 2
New drugs for treating dyslipidemias. From small molecules to small interfering RNAs
Masana, L., & Ibarretxe, D. (2024) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2025.100739 · Cited by 1
The Association Between Lipoprotein(a) and Atherosclerotic Cardiovascular Disease Severity
Li, Z., Wang, D., Li, F., Wang, Y., Wang, Z., zeng, K., Yan, S., Liu, D., pei, D., Cao, Y., et al. (2026) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm46656 · Cited by 1
“Across six randomized trials comprising 444 participants, consolidated evidence indicated that treatment with mipomersen produced marked reductions in LDL-C, non-HDL-C, apolipoprotein B, and Lp(a) [17].”
Lakshmanan, M. (2021) · Introduction to Basics of Pharmacology and Toxicology · doi:10.1007/978-981-33-6009-9_31 · Cited by 1
Hipercolesterolemia Familiar: uma nova abordagem no tratamento
Duarte, R. A. S. (2017) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/bm3k-9d59 · Cited by 1
OBSOLETE: Familial Hypercholesterolemia
Catapano, A. L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.99567-9
Hameed, Q. A., Chen, L., Yang, M., Afzali, J., & Ma, G. (2020) · World Journal of Cardiovascular Diseases · doi:10.4236/wjcd.2020.102012
“Moreover, novel drugs, including PCSK9 inhibitors, as well as antisense oligonucleotide for Apo-A, have exhibited efficacy in decreasing Lp(a) substantially [28] [29].”
BackgroundManchugondanahalli, S. K. (2020) · DR-NTU (Nanyang Technological University) · doi:10.32657/10356/137354
Lin, C., Chien, S., Lin, Y., Wu, Y., Su, C., & Yeh, H. (2017) · 內科學誌 · doi:10.6314/jimt.2017.28(4).05
Στρατηγικές RNA θεραπείας σε μονογονιδιακά νοσήματα
PITTA, P. (2023) · University of Thessaly Institutional Repository (University of Thessaly) · doi:10.26253/heal.uth.39177
Metadata
- Authors
- Li, N., Li, Q., Tian, X.-Q., Qian, H.-Y., & Yang, Y.-J.
- Affiliations
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Venue
- American Journal of Cardiovascular Drugs
- Published
- 2014-06-11
- Volume
- 14
- Issue
- 5
- Pages
- 367-376
- ISSN
- 1175-3277 (ISSN-L)
- 1179-187X
- OpenAlex
- W2133781918
- Cited by
- 45
- References
- 40
- Citations by year
- 2024: 6 · 2023: 1 · 2022: 3 · 2021: 5 · 2020: 3 · 2019: 3 · 2018: 3 · 2017: 5 · 2016: 7 · 2015: 7 · 2014: 2
- FWCI
- 1.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- American Journal of Cardiovascular Drugs (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- mipomersen, hypercholesterolemia, apolipoprotein B, LDL cholesterol, non-HDL cholesterol, lipoprotein(a), apolipoprotein B-containing lipoproteins, drug safety, injection site reactions, flu-like symptoms, elevated liver enzymes, PCSK9 inhibition
- MeSH terms
- Adult, Anticholesteremic Agents, Female, Humans, Hypercholesterolemia, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Oligonucleotides, Randomized Controlled Trials as Topic, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.